Alzheimer’s disease

Dec 13, 2018

Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclin...

Dec 05, 2018

Coconut oil and dementia  Presently, we have a lack of evidence in displaying coconut oil playing any role in treating dementia or its symptoms. Albeit, there have been some claims regarding coconut oil that it could be used as a treatment, or even a cure, for Alzheimer's disease. But, currently, there is not e...

Oct 11, 2018

Cytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles  CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufactur...

Oct 11, 2018

Streamlined solutions provided by Cognitive Clinical Trials (CCT) related to the treatment and prevention of Alzheimer’s disease Congnitive Clinical Trials (CCT) has introduced a new research model that prevail over the top obstacles being faced by the researchers related to the treatment and prevention of Alzheime...

Jan 02, 2018

Connection between Immune cells in the brain and Alzheimer’s disease The spreading of pathology within and between brain areas is a hallmark of neurodegenerative disorders. In patients with Alzheimer’s disease, deposition of amyloid-β is accompanied by activation of the innate immune system and involves the inflamma...

Jan 02, 2018

British scientists looking forward to treat Alzheimer’s disease through diabetes drug A group of British scientists are looking for the treatment of Alzheimer’s disease in an unlikely source i.e. a drug used for treating Type 2 Diabetes. The team, from Lancaster University, has reported that an experimental three-p...

Sep 27, 2016

US FDA grants approval for Novartis' Ilaris to treat Periodic Fever Syndromes Novartis received approval to market its Periodic Fever Syndrome drug Ilaris (cancakinumab). The drug targets the syndrome, and will be used to treat a group of diseases that cause serious recurrent fever and pathogenic inflammation throug...

Oct 13, 2015

Introduction: Any disease that affects less than 200,000 patients or 1 in 1500 is termed as a rare disease. There are around 5000 to 8000 rare disease reported, out which only 10% have cure. According to the European Organization for rare disease, 80% of rare diseases are genetic in nature. Some of the rare disease...